Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy

University Hospital, Ghent58 enrolled

Overview

Maintaining adequate perfusion pressure and oxygen supply is essential for organ survival. Splanchnic hypoperfusion during the perioperative period in abdominal surgery may result in mucosal ischemia with increased permeability of the gut barrier. Additionally, the liver is also sensitive for hypoxemia and hypoperfusion, especially during liver surgery. Anesthetics (such as propofol or sevoflurane) have a cardiovascular depressant effect, resulting in a reduction of cardiac output (CO). Dobutamine is used to counteract myocardial depressant effect of anesthetics. Additionally, dobutamine is frequently used during abdominal surgery to maintain splanchnic perfusion. Dobutamine could increase hepatic blood flow (HBF) indirectly by increasing cardiac output or directly by stimulating adrenergic receptors in the splanchnic circulation. The hepatic circulation has a large number of alpha and beta adrenergic receptors and could be sensitive for adrenergic stimulation such as dobutamine. Hence, dobutamine could have a direct effect on the hepatic vasculature. The aim of the study is to evaluate the effect of dobutamine on hepatic blood flow during goal directed hemodynamic therapy and to distinguish between potential direct and indirect effects.

All patients receive standardized anesthesia care for pancreaticoduodenectomy according to the existing departmental protocol for these interventions. All patients receive individualized goal-directed hemodynamic therapy based on the transpulmonary thermodilution technique. At designated times, hemodynamic variables will be recorded. These include : * Heart rate (bpm) * Central venous pressure (mmHg) * Systolic arterial pressure (mmHg) * Diastolic arterial pressure (mmHg) * Mean arterial pressure (mmHg) * Cardiac index (L/min/m2) * Pulse pressure variation (PPV) * Stroke volume variation (SVV) Measurements of hepatic flow and pressure will be performed by the surgeon : * Hepatic flow : in the hepatic artery (arterial HBF) and portal vein (portal HBF). * Pressure measurements : in portal vein (PPorta) and caval vein (PCava) Measurements will be done : * without inotropic support * with infusion of dobutamine 2mcg/kg/min * with infusion of dobutamine 5mcg/kg/min

Study Type

INTERVENTIONAL

Allocation

Purpose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult ≥ 18 years ≤ 80 years (female or male). * ASA I - II - III. * Able to comprehend, sign and date the written informed consent document to participate in the clinical trial. * Patient is scheduled for pancreaticoduodenectomy (Whipple's procedure). Exclusion Criteria: * Allergy to the medication dobutamine. * Renal insufficiency (SCr \> 2 mg/dL). * Severe heart failure (EF \< 25%). * Hemodynamic unstable patients. * Atrial fibrillation. * Sinus tachycardia \> 100 bpm on pre-operative electrocardiogram. * Sepsis. * BMI \> 40. * Severe coagulopathy (INR \> 2). * Thrombocytopenia (\< 80 x 103 /mcL). * End stage liver disease and/or portal hypertension. * Pregnancy and breastfeeding women.

Outcomes

Primary Outcomes

change in portal and arterial hepatic blood flow during goal-directed hemodynamic therapy with dobutamine

flow measurements with echo probe